Latest News

Riassunto: Terns Pharmaceuticals ottiene dalla FDA la designazione di farmaco soggetto a procedura abbreviata per TERN-101, agonista del recettore FXR per il trattamento della NASH


FOSTER CITY, California, e SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals, Inc., multinazionale biofarmaceutica dedita alla scoperta e allo sviluppo di terapie innovative per il trattamento della steatosi epatica non alcolica (non-alcoholic steatohepatitis, NASH) e del cancro, ha annunciato oggi che TERN-101, agonista sperimentale del recettore farnesoide X (farnesoid X receptor, FXR), ha ottenuto dall’ente statunitense preposto al controllo dei farmaci e degli alimenti (Food and Drug Adminis

Source link

Related posts

Simple Ways To Keep Your Mind Healthy Amid Stressful Times

Newsemia

Bacteria keep us healthy – but could they keep us young?

Newsemia

Pregnant women with type 1 diabetes are at greater risk of preterm birth

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World